构建发现的基础设施：加速肾癌研究的临床试验联盟.pdf

1、Kidney Cancer Research ConsortiumERIC JONASCH,MD ON BEHALF OF THE KCRC TEAM AND INVESTIGATORSDr.David McDermottDr.Hans HammersDr.Naomi HaasDr.Eric JonaschDr.Brian RiniDr.Ulka VaishampayanDr.Daniel GeorgeThe KCRC TeamOur MissionThe key emphasis of the Kidney Cancer Research Consortium(KCRC)is to crea

2、te create mechanistic,hypothesis testing and hypothesis generating clinical trials mechanistic,hypothesis testing and hypothesis generating clinical trials that link identifiable biological characteristics of Renal Cell Carcinoma(RCC)identifiable biological characteristics of Renal Cell Carcinoma(RC

3、C)subtypes to to specific treatments and treatment strategiesspecific treatments and treatment strategies,and that help develop robust robust predictive biomarkers.predictive biomarkers.Creating a unique,tailored and specific infrastructure unique,tailored and specific infrastructure for RCC trials

4、is essential to provide the necessary focus on these goalsnecessary focus on these goals,and to ensure close collaboration ensure close collaboration between investigators invested in developing the next generation of therapies developing the next generation of therapies for patients with RCC.CDMRP/

5、USAMRMCKCRPCoordinating CenterLauren WoodManager,Clinical Protocol AdministrationMDACC (CTS)ACC(CTS)UTSWCC(CTS)BIDMC(CTS)Steering Committee(Oversight)EAB (Governance)CDMRP TitleMedha Darshan CDMRP Science OfficerTheresa Miller,PhDProgram ManagerDr.Walter StadlerKCRP Programmatic PanelSusan PoteatKCR

6、P Programmatic PanelSteering Committee AffiliationDr.Eric JonaschMDACCDr.Naomi HaasACCDr.Hans HammersUTSWCCDr.David McDermottBIDMCDr.Ulka VaishampayanMichiganDr.Brian RiniVUMCDr.Daniel GeorgeDukeDewey StringerPatient AdvocateBrenda KnappPatient AdvocateEAB MembersAffiliationMichael Atkins,MDGeorgeto